Heterotaxia syndromes and 22q11 deletion

In a recent issue of your journal we read with interest the very accurate review by Penman Splitz et al. on defects of left-right asymmetry. The authors correctly reported that in patients with heterotaxia (asplenia and polysplenia syndromes), conotruncal defects are one of the more frequent heart malformations. It is well known that 22q11 deletion has been described in a subgroup of patients with conotruncal anomalies in the setting of DiGeorge Syndrome and velocardiofacial syndromes. In the paper of Penman Splitz et al. was reported (personal communication to the authors) that the same microdeletion has been found in two patients, one with dextrocardia and one with left isomerism (polysplenia syndrome).

Since 1993 we have performed clinical and molecular evaluation of all patients with conotruncal anomalies observed at our hospital, including 20 cases with heterotaxia. Fifteen had asplenia syndrome and five polysplenia. All patients underwent phenotypic and cardiac examinations. Fluorescent in situ hybridisation was used for detecting 22q11 deletion.

No patients had phenotypic features of DiGeorge or velocardiofacial syndromes, and the genetic study did not show 22q11 deletion in any case. Our experience suggests that the conotruncal anomalies in the setting of heterotaxy syndromes are not related to 22q11 deletion, and are probably secondary to distortion of cardiac looping or to the anomaly of the situs itself. Different gene(s) and different developmental mechanisms may be involved in the pathogenesis of conotruncal anomalies in patients with situs solitus and in those with laterality defects.

BRUNO MARINO
MARIA CRISTINA DIGILIO
ALDO GIANNOTTI
Pediatria Cardiologica e Medical Genetics,
Ambulatorio Genetico, Piazza S Onofrio 4,
00165 Roma, Italy

First report of three cystic fibrosis patients homozygous for the 1717-1G→A mutation

We report the identification for the first time of three cystic fibrosis (CF) patients homozygous for the 1717-1G→A mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

The clinical presentation of CF varies widely, the most common characteristics being chronic obstructive lung disease, raised electrolyte and pancreatic insufficiency (PI). About 15% of patients display pancreatic sufficiency (PS).

The isolation of the CFTR gene has made it possible to identify the main disease causing mutation, AF508, accounting for about 70% of molecular defects in the world population, and over 600 rare presumptive mutations (CF Genetic Analysis Consortium). Among these, the 1717-1G→A mutation is implicated in a base change at the 3' end of the consensual sequence of intron 10. It was first reported in a patient of Celtic origin and since then it has been detected in other populations, having an overall frequency of 1.1%.

To date, a clinical correlation for this mutation has been defined only in patients who are compound heterozygotes for AF508, who display a similar pancreatic and pulmonary phenotype to that of homozygotes for AF508.

In this report we describe the first three patients found to be homozygous for the 1717-1G→A mutation. They showed early pancreatic insufficiency (ozyme: steatorrhea) and males of two had early onset of pulmonary symptoms, but with subsequent minimal lung involvement progression. These clinical findings suggest that this mutation might pre-dispose to a milder respiratory course.

Two patients (cases A and B) regularly attended the Milan CF Centre at the Department of Pediatrics, University of Milan; the third patient (case C) is followed at the Naples CF Centre, Pediatrics Department, University of Naples.

The three 1717-1G→A homozygous patients include: case A, female, born at term (birth weight 3550 g) to healthy, non-consanguineous parents. At birth, she presented with meconium ileus, which was surgically treated with a 10 cm ileal resection. She had a high immune reactive trypsinogen (IRT) value at 5 days of life (173 ng/ml, normal value <40 ng/ml) and CF was confirmed by a positive polyclonal ioprophosphatase sweat test (112 mmol/l) at 6 months of age. Treatment for CF was started at 2 months with pancreatic enzyme supplementation (Pancrease®) and chest physiotherapy (positive expiratory pressure technique). At the latest clinical CF Centre follow-up attendance, she was normal on examination, weight was 14 kg (75th centile), height 94 cm (97th centile). Good nutritional status was obtained with a low dose of pancreatic enzymes (175 U/kg/day of pancrelipase) associated with a high fat content diet. A chest x ray showed only minimal thickening of the bronchial walls in the lower lobes. Staphylococcus aureus was not isolated. Liver ultrasound was in the normal range.

The second patient, case B, a male, was born at term (birth weight 2850 g) to healthy, non-consanguineous parents. CF was confirmed with a molecular diagnosis at 2 months of age. He required four hospital admissions in the first months of life. CF was confirmed by a positive polyclonal ioprophosphatase sweat test (80, 105 mmol/l chloride). Regular follow up at the Milan CF Centre. CF Centre treatment was started at 6 months, with pancreatic enzymes, mucolytic and bronchodilator aerosol, and physiotherapy. He grew impressively after the start of the treatment, body weight reaching the 50th centile at 2 years, and developing along the 97th centile from 5 years. At the last clinical visit, he was asymptomatic, not clubbed, his weight was 24.5 kg (50th centile) and his height 113 cm. Steatorrhea was absent and fat absorption coefficient was 93%, with 1061 U/kg/day of pancrelipase and a high fat content diet. A chest x ray showed only basal bronchial wall thickening. Staphylococcus aureus was not isolated from sputum samples. He needed only one therapeutic antibiotic course per year for upper respiratory tract infection and the clinical course was mild, with no further hospital admissions after his referral to our Centre following diagnosis. Lung function tests were always in the normal range. As compliance with chest physiotherapy was poor, daily sporting activities were encouraged. No alterations in nutritional indices were ever noted. Liver function tests were normal until July 1995, when serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALAT), and glutamynotransferase (GLT) were slightly increased (158 U/l, 47 U/l, and 53 U/l, with normal values less than 37 U/l, 41 U/l, and 49 U/l). Ultrasound liver examination showed early signs of liver disease, so ursodeoxycholic acid therapy was prescribed.

The third patient, case C, a female, was born to healthy, non-consanguineous parents. Both paternal and maternal ancestors came from the same small city near Naples. Cystic fibrosis was presented early with failure to thrive, malabsorption, and bronchiolitis, and she had ileotectomy in the upper left lobe, leading to hospital admissions at 1 and 3 months of age. CF was confirmed by a positive polyclonal ioprophosphatase sweat test (93 mmol/l chloride). Regular follow up at the CF Center and treatment was started with pancreatic enzyme...